CHA Vaccine Research Institute (KOSDAQ:261780)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,635.00
0.00 (0.00%)
At close: Feb 19, 2026

KOSDAQ:261780 Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
158.62370.66294.12179.4850077.8
Other Revenue
-0-0-0-0--
158.62370.66294.12179.4850077.8
Revenue Growth (YoY)
-57.21%26.02%63.87%-64.10%542.70%-38.31%
Cost of Revenue
14.723.9334.519-13.01
Gross Profit
143.92346.73259.62160.4950064.79
Selling, General & Admin
1,8311,8742,1972,3573,1991,038
Research & Development
8,9935,6783,9493,8553,1403,124
Amortization of Goodwill & Intangibles
25.8322.588.549.1410.7613.87
Operating Expenses
11,2068,0436,6796,6306,5854,299
Operating Income
-11,062-7,696-6,419-6,469-6,085-4,234
Interest Expense
-2,103-1,288-2,631-2,567-2,122-837.2
Interest & Investment Income
1,0931,3842,2821,017179.8877.17
Currency Exchange Gain (Loss)
-1.4610.022.670.020.170.04
Other Non Operating Income (Expenses)
-2,711-2,8914,7031,198-10,520-1,278
EBT Excluding Unusual Items
-14,785-10,481-2,063-6,821-18,546-6,272
Gain (Loss) on Sale of Investments
258.3166.77-40.4105.84125.7731.7
Gain (Loss) on Sale of Assets
-----0.32
Pretax Income
-14,526-10,414-2,103-6,715-18,420-6,240
Income Tax Expense
-275.5-275.5-353.77---
Net Income
-14,251-10,138-1,749-6,715-18,420-6,240
Net Income to Common
-14,251-10,138-1,749-6,715-18,420-6,240
Shares Outstanding (Basic)
272727262318
Shares Outstanding (Diluted)
272727262318
Shares Change (YoY)
0.85%1.10%0.26%13.39%30.03%-
EPS (Basic)
-531.06-378.30-66.00-254.00-790.00-348.00
EPS (Diluted)
-531.06-378.30-66.00-254.00-790.00-348.00
Free Cash Flow
-11,198-8,275-5,572-5,636-5,419-4,007
Free Cash Flow Per Share
-417.30-308.76-210.20-213.18-232.41-223.48
Gross Margin
90.73%93.55%88.27%89.42%100.00%83.28%
Operating Margin
-6974.08%-2076.42%-2182.53%-3604.36%-1216.93%-5442.95%
Profit Margin
-8984.47%-2735.23%-594.82%-3741.36%-3684.01%-8021.36%
Free Cash Flow Margin
-7059.76%-2232.46%-1894.38%-3140.08%-1083.83%-5151.23%
EBITDA
-10,679-7,205-5,886-6,052-5,839-4,094
D&A For EBITDA
382.64491.22533.31417.36245.49140.16
EBIT
-11,062-7,696-6,419-6,469-6,085-4,234
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.